SUBSEQUENT EVENTS |
6 Months Ended |
|---|---|
Mar. 31, 2026 | |
| SUBSEQUENT EVENTS [Abstract] | |
| SUBSEQUENT EVENTS |
14.
SUBSEQUENT EVENTS
On April 7, 2026, the Company and its subsidiaries entered into the First Amendment to the Credit Agreement dated as of December 29, 2025 which allowed for the acquisition of the antibody product line from BioPorto A/S described below. The First Amendment also updated certain definitions.
On April 8, 2026, the Company acquired an
antibody product line from BioPorto A/S for $9,000 in cash funded from the RCF
and $1,500 in potential future earnouts. Acquired inventory and future sales
will be included in the Company’s Life Sciences segment. On May 5, 2026, the Company’s board authorized the purchase of up to 50,000 additional shares in Rubicon in the public market or through privately negotiated transactions. The size and timing of any purchases will be based on a number of factors, including price and business and market conditions.
|